Ishii, Ryotaro http://orcid.org/0000-0002-6976-1081
Schwedt, Todd J. http://orcid.org/0000-0002-7780-7086
Trivedi, Meesha http://orcid.org/0000-0002-0786-9417
Dumkrieger, Gina http://orcid.org/0000-0001-9519-5370
Cortez, Melissa M. http://orcid.org/0000-0001-5015-441X
Brennan, K. C.
Digre, Kathleen http://orcid.org/0000-0003-2011-418X
Dodick, David W. http://orcid.org/0000-0002-9486-6790
Funding for this research was provided by:
American Migraine Foundation
Article History
Received: 1 June 2021
Accepted: 9 July 2021
First Online: 22 July 2021
Declarations
:
: Ethic approval was give by the Mayo Clinic Institutional Review Board.
: Not applicable.
: Ryotaro Ishii has nothing to disclose.David W. Dodick reports the following conflicts within the past 12 months: Consulting: AEON, Amgen, Clexio, Cerecin, Cooltech, Ctrl M, Allergan, Alder, Biohaven, GSK, Linpharma, Lundbeck, Promius, Eli Lilly, eNeura, Novartis, Impel, Satsuma, Theranica, WL Gore, Nocira, XoC, Zosano, Upjohn (Division of Pfizer), Pieris, Praxis, Revance, Equinox. Honoraria: CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, Southern Headache Society (MAHEC), WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI). Stock Options/Shareholder/Patents/Board of Directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (Options), Theranica (Options), Second Opinion/Mobile Health (Options), Epien (Options/Board), Nocira (options), Matterhorn (Shares/Board), Ontologics (Shares/Board), King-Devick Technologies (Options/Board), Precon Health (Options/Board). Patent 17189376.1–1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis.Meesha Trivedi has nothing to disclose.Gina Dumkrieger has received research support from Amgen.Melissa Cortez served as a consultant for Eli Lilly, and has received research funding from Amgen Early Investigator Award in Migraine Research and National Institutes of Health (1K23NS105920, 1R21HD100897).KC Brennan served as an advisory board for Allergan/Abbvie.Kathleen Digre serves on the Board of Directors for the American Headache Society and is supported in part by an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah.Todd Schwedt has received personal compensation for serving as a consultant or advisory board member within the past 12 months from Abbvie/Allergan, Biohaven, Click Therapeutics, Eli Lilly, Equinox, Lundbeck, and Novartis. He has stock options in Aural Analytics and Nocira. He has received research funding from: Amgen, American Migraine Foundation, Arizona State University, Henry Jackson Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, and U.S. Department of Defense. He serves on the Board of Directors for the American Headache Society and the International Headache Society.